Experimental Treatment with SAR’579/IPH6101 Shows Promising Early Results in Patients with Relapsed/Refractory AML

Innate Pharma SA is proud to announce that the latest research concerning its SAR443579 drug’s benefits for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia was published on the ASCO 2023 Annual Meeting website!

The research results indicated that SAR443579 is well tolerated up to doses of 3 mg/kg, offering tangible clinical benefit to these conditions. We are excited to witness the efficacy and feasibility of this groundbreaking drug and hope to continue to lead the way in the development of innovative drugs for life-threatening diseases.

Innate Pharma is thrilled to see the positive initial results of Sanofi’s dose escalation Phase 1/2 study for their SAR’579/IPH6101 CD123 treatment in relapsed/refractory acute myeloid leukaemia, with both clinical responses and good tolerability observed.

The promising clinical data from SAR’579 is a major milestone, and they look forward to a full presentation of this trial at the 2023 ASCO Annual Meeting, as well as further updates on other ANKET® platform programs entering the clinic.

Sanofi and Innate scientists have come together to create SAR’579, an innovative investigational drug founded on the ANKET® platform and designed to target CD123 to unleash the power of NK cells. This is a groundbreaking breakthrough, pushing the boundaries of what is possible when envisioning treatments for cancer.

Sanofi is thrilled to be presenting early clinical results of SAR’579 at the 2023 ASCO meeting. Global Head, Oncology Development, Peter C. Adamson MD, wants to express his sincere thanks to their investigators leading the clinical effort and the courageous patients and families who have volunteered to take part in the trial. Let’s look forward to the continued development and success of SAR’579!

About ANKET®

Innate’s proprietary platform, BLANKET®, is pioneering the development of personalized treatments that target certain types of cancer using next-generation, multi-specific natural killer (NK) cell engagers. This cutting-edge therapy harnesses the power of antibodies to bolster the body’s own NK cells, leading to potentially life-saving results.

This revolutionary technology is changing the game in the fight against cancer, by introducing a new class of molecules that can trigger synthetic immunity. This powerful tool is ideal for a variety of applications, and is offering us fresh hope in the fight against this devastating disease.

About the Innate-Sanofi agreement:

In a groundbreaking collaboration and licensing agreement with Sanofi, Innate has set out to develop cutting-edge multi-specific antibodies that empower NK cells through NKp46 and CD16 receptors to eradicate tumors. This project represents a major scientific advance and a promising new treatment pathway.

Innate Pharma is poised to receive up to €400 million in milestone payments and royalties on net sales from Sanofi, in accordance with their 2016 research collaboration and licensing agreement. This collaboration encompasses the development, manufacturing, and commercialization of products including IPH6101/SAR’579 (CD123 NK Cell Engager) and IPH6401/SAR’514 (BCMA NK Cell Engager). This collaboration offers Innate Pharma the potential to reap great rewards.

In December 2022, Innate and Sanofi entered a new, lucrative license agreement. The agreement covers IPH62 (B7-H3 NK Cell Engager) and two options. To start, Innate would receive a €25m upfront payment, and could become eligible for an additional €1.35bn in milestones, provided preclinical, clinical, regulatory and commercial requirements are achieved.

Additionally, should any of the candidates be commercialized, Innate would receive a share of the profits. Finally, Sanofi is fully responsible for the development, manufacturing and commercialization of the candidate works.

About Innate Pharma

Innate Pharma S.A. is an innovative, clinical-stage biotechnology company making groundbreaking strides in cancer treatment. By leveraging the body’s natural immune system through its patented ANKET® (Antibody-based NK cell Engager Therapeutics) platform, Innate Pharma is creating immunotherapies that show great promise in helping patients fight cancer.

Innate Pharma is a trailblazing biopharmaceutical company working to revolutionize the healthcare industry. By partnering with industry giants like Sanofi and AstraZeneca, as well as renowned research institutions, Innate Pharma is committed to fast-tracking the development of novel treatments that will offer meaningful improvement in the quality of life for patients.

Innate Pharma, with its headquarters in the beautiful port city of Marseille, France, and its US office located in Rockville, Maryland, has achieved success across both the Euronext Paris and Nasdaq US stock markets. Positioned as a leader in the biotechnology industry, its innovative approach has allowed it to become a recognized name globally.

Leave a Comment